“…Consequently, the estimation of the drug product is essential in the regulated pharmaceutical industry. To date, several analytical methods, primarily for the estimation of PGB (Abu‐Qare & Abou‐Donia, 2001; Barber et al, 1979; Ellin et al, 1982; Giovanni et al, 2019; Matsunaga et al, 1987) and SBN (Abdollahpour et al, 2010; Boukarim et al, 2009; Can et al, 2011; Ettaboina, Katakam, & Dongala, 2022; Ettaboina, Nakkala, & Chathalingath, 2022; Galli & Barbas, 2004; Hewala, 1994; Jwahaeng et al, 2018; Katakam, Ettaboina, & Dongala, 2021; Katakam, Ettaboina, & Marisetti, 2021; Lakka et al, 2021, 2022; Lakka & Goswami, 2012; Narasimha et al, 2011; Narasimha & Chandrasekar, 2019; Navneet et al, 2012; Parvateesam et al, 2023; Pylypiw & Grether, 2000; Shabir, 2011; Siva et al, 2022), have been developed using various analytical techniques. None of the methods are inherently stability‐indicating for the estimation of PGB and SBN in liquid oral dosage forms.…”